High ORR with sequential regimen in CLL



Micrograph showing CLL
A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), results of the CLL2-BAG study suggest. Patients who received bendamustine followed by obinutuzumab and venetoclax achieved an ORR of 95%, and 87% of them were negative... [Read Article]

CHMP recommends new indication for obinutuzumab



Micrograph showing FL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization for obinutuzumab (Gazyvaro). The new proposed indication is for obinutuzumab in combination with chemotherapy for patients with previously untreated, advanced follicular lymphoma (FL). This would be followed by obinutuzumab maintenance in patients... [Read Article]

CAR T-cell therapy ‘highly effective’ in high-risk CLL



Cameron Turtle, MBBS, PhD
Photo by Robert Hood,
Fred Hutchinson Cancer
Research Center
A chimeric antigen receptor (CAR) T-cell therapy is “highly effective” in high-risk patients with chronic lymphocytic leukemia (CLL), according to researchers. The CD19 CAR T-cell therapy, JCAR014, produced an overall response rate of 71% and a complete response (CR) rate... [Read Article]

GAD-M produces high ORR in treatment-naïve ENKTL



14th International Conference
on Malignant Lymphoma
A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-cell lymphoma (ENKTL). Treatment with gemcitabine, PEG-asparaginase, dexamethasone, and methotrexate (GAD-M) produced a 94% overall response rate (ORR) and an 83% complete response (CR) rate in this trial. Responses and... [Read Article]

Drug granted PRIME access as treatment for DLBCL



Micrograph showing DLBCL
The European Medicines Agency (EMA) has granted polatuzumab vedotin access to the agency’s PRIority MEdicines (PRIME) program. The access is for polatuzumab vedotin when used in combination with rituximab and bendamustine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin is an anti-CD79b antibody drug... [Read Article]

CAR T-cell therapy shows early promise in DLBCL



Diffuse large B-cell lymphoma
The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with relapsed/refractory, aggressive diffuse large B-cell lymphoma (DLBCL), according to an investigator from the TRANSCEND trial. In this phase 1 trial, JCAR017, given after lymphodepleting chemotherapy, produced an overall response rate (ORR) of... [Read Article]

Single-dose NEPA found non-inferior to aprepitant/granisetron



Nurse hanging bags
of chemotherapy drugs
Photo by Bill Branson
In a head-to-head study comparing a single-dose oral antiemetic to a 3-day oral regimen, the single dose has shown itself to be non-inferior to the multi-day regimen in preventing chemotherapy-induced nausea and vomiting (CINV). The investigators evaluated netupitant/palonosetron (NEPA) against aprepitant/granisetron (APR/GRAN) in patients on... [Read Article]